Champions Oncology, Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended April 30, 2016; comparison is fiscal 2015. This is an annual report, not a standalone 2015 Q4 filing. Champions develops TumorGraft patient-derived tumor models and related services for oncology drug development (TOS) and personalized treatment support (POS).
Financial results and liquidity
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Revenue | $11.18 million | $8.86 million | +26.2% |
| TOS revenue | $9.21 million | $7.20 million | +27.9% |
| POS revenue | $1.97 million | $1.66 million | +18.6% |
| Operating loss | $10.32 million | $13.24 million | Loss narrowed 22.1% |
| Net loss | $10.45 million | $13.14 million | Loss narrowed |
| Basic and diluted loss per share | $1.20 | $2.20 | Improved |
| Net cash used in operating activities | $6.45 million | $9.63 million | Use decreased |
- Margins: TOS gross margin was 28.5%, down from 31.9%; management attributed the decline to costs recognized ahead of associated revenue. POS gross margin improved to negative 6.6% from negative 64.3%, but remained negative.
- Year-end liquidity: Cash and cash equivalents were $2.59 million; current assets were $4.34 million and current liabilities $5.31 million. Management reported approximately $1 million of negative working capital. Stockholders’ equity was $238,000.
- Cash flow and spending: Investing activities used $322,000; financing activities provided $2,000. R&D expense was $4.19 million, down 13.4%. Cash declined from $9.36 million at prior year-end.
- Debt and obligations: The filing reports no off-balance-sheet debt or similar obligations. A laboratory-equipment capital lease had $83,000 of present-value payments outstanding at April 30, 2016. Deferred revenue was $3.14 million.
Material changes and management commentary
- Revenue growth was principally driven by TOS, with increased study bookings in both number and size. TOS represented 82.4% of revenue.
- POS revenue rose overall, but core activity weakened: implants fell 42% to 143 and patients receiving panels fell 47% to 48. Growth in sequencing and tumor-board revenue offset declines in implant and drug-panel revenue. Management said POS would not be a focus of future growth.
- Total costs and operating expenses decreased 2.7% to $21.50 million, including lower R&D, sales and marketing, and general and administrative expense; TOS cost of sales increased 34.4% with higher study volume.
- The company reported a net loss in both years and an accumulated deficit of $62.47 million. Management expects operating losses to continue and stated that year-end cash alone, together with subsequent financing, was expected to fund operations through at least August 2017.
- After year-end, a June 15, 2016 public offering of 2,258,749 shares generated approximately $4.3 million net proceeds. The company reported $5.5 million cash at June 30, 2016 and planned to use proceeds for TumorGraft R&D, working capital, and general corporate purposes.
Outlook, risks, and unusual items
- No specific revenue, earnings, or margin guidance is provided. The strategy emphasizes expanding the TumorBank, developing humanized-immune-system ImmunoGrafts, and increasing the scale of TOS studies.
- Management’s runway estimate depends on operating performance and costs; the filing warns that further capital may be required and that additional financing may not be available on acceptable terms. The company has a history of losses and may never achieve profitability.
- Nasdaq had notified the company of a stockholders’ equity listing deficiency. Nasdaq accepted a compliance plan and granted an extension; failure to demonstrate compliance in the specified subsequent filing could result in delisting.
- Key risks include intense competition, an unpatented TumorGraft platform, potential FDA oversight of laboratory-developed tests and other regulatory requirements, dependence on customer study plans and a limited sales force, lack of third-party reimbursement for POS services, and reliance on laboratory facilities and live mouse colonies.
- One TOS customer accounted for 17.6% of FY2016 revenue; two customers represented 43.0% of accounts receivable at year-end. Deferred revenue included $67,000 related to possible replacement of licensed tumors, down from $258,000; the related contract was substantially completed.
- Other unusual or relevant items: FY2015 included a $981,000 gain from warrant fair-value changes and a $586,000 warrant modification charge; these did not recur in FY2016. The company also disclosed a possible Section 382 limitation on use of tax-loss carryforwards and a July 2016 senior-management option exchange whose accounting impact was still being assessed.
Investor facts to verify
- Whether TOS bookings and study sizes continue to support growth, and whether TOS margins recover as expenses and revenue are recognized.
- Actual cash burn, progress against management’s stated August 2017 runway, and any need for additional capital or further dilution.
- Compliance with Nasdaq’s stockholders’ equity requirement and the outcome of the specified follow-up review.
- Evidence supporting the claimed predictive value of TumorGrafts, and any FDA or other regulatory changes affecting POS services.
- Customer concentration, cancellations or modifications of customer studies, and the continuing negative gross margin of POS.